These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29735308)

  • 1. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
    Alric L; Ollivier-Hourmand I; Bérard E; Hillaire S; Guillaume M; Vallet-Pichard A; Bernard-Chabert B; Loustaud-Ratti V; Bourlière M; de Ledinghen V; Fouchard-Hubert I; Canva V; Minello A; Nguyen-Khac E; Leroy V; Saadoun D; Trias D; Pol S; Kamar N
    Kidney Int; 2018 Jul; 94(1):206-213. PubMed ID: 29735308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.
    Atsukawa M; Tsubota A; Toyoda H; Takaguchi K; Kondo C; Okubo T; Hiraoka A; Michitaka K; Fujioka S; Uojima H; Watanabe T; Ikeda H; Asano T; Ishikawa T; Matsumoto Y; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Mikami S; Tanaka Y; Kumada T; Iwakiri K
    J Gastroenterol Hepatol; 2019 Feb; 34(2):364-369. PubMed ID: 30144366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
    Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
    Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
    Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
    Huang CF; Hung CH; Cheng PN; Bair MJ; Huang YH; Kao JH; Hsu SJ; Lee PL; Chen JJ; Chien RN; Peng CY; Lin CY; Hsieh TY; Cheng CH; Dai CY; Huang JF; Chuang WL; Yu ML
    J Infect Dis; 2019 Jul; 220(4):557-566. PubMed ID: 30957170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
    Flamm SL; Bacon B; Curry MP; Milligan S; Nwankwo CU; Tsai N; Younossi Z; Afdhal N
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1511-1522. PubMed ID: 29665097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.
    Laguno Centeno M; Alvarez B; Martínez-Rebollar M; de la Mora L; Prieto L; de Lazzari E; González-Cordón A; Torres B; Cabello A; Gorgolas M; Mallolas J
    Gastroenterol Hepatol; 2021 Mar; 44(3):191-197. PubMed ID: 33041087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
    Wei L; Jia JD; Wang FS; Niu JQ; Zhao XM; Mu S; Liang LW; Wang Z; Hwang P; Robertson MN; Ingravallo P; Asante-Appiah E; Wei B; Evans B; Hanna GJ; Talwani R; Duan ZP; Zhdanov K; Cheng PN; Tanwandee T; Nguyen VK; Heo J; Isakov V; George J;
    J Gastroenterol Hepatol; 2019 Jan; 34(1):12-21. PubMed ID: 30311701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    Ji Q; Chu X; Zhou Y; Liu X; Zhao W; Ye W
    J Med Virol; 2022 Feb; 94(2):675-682. PubMed ID: 34599755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
    J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    Tsai TC; Deng ST; Hsu CW
    J Med Virol; 2020 Feb; 92(2):219-226. PubMed ID: 31599455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.
    Cheng PN; Chen CY; Yu ML; Lin CC; Lin CY; Peng CY; Tseng KC; Lo CC; Tseng IH; Liu CJ
    J Microbiol Immunol Infect; 2021 Aug; 54(4):588-595. PubMed ID: 32499107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.